Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Peregrine receives approval for Phase II lung cancer study
The primary objective of the multi-center clinical trial is to assess the overall tumor response rate in non-small cell lung cancer (NSCLC) patients treated with the combination of
The primary objective of the multi-center clinical trial is to assess the overall tumor response rate in non-small cell lung cancer (NSCLC) patients treated with the combination of
The US District Court of New Jersey has postponed the trial date. The general terms and status of the anticipated settlement will not be disclosed by either party
The primary objective of this trial is to assess the efficacy, measured as first-year height velocity, and safety of three different combination regimens of growth hormone and IGF-1
The new product is a combination therapy that joins together both Hadasit and BWH/HMS intellectual property. This is the first official cooperation between Hadasit, Hadassah, Harvard Medical School
The Reliant monitor is powered by Cheetah’s unique, patented Bioreactance technology, which has been used effectively in over 1,000 patients in various clinical settings including hemodynamic monitoring, heart
This was the last step necessary for Jiangling to be eligible for Good Manufacturing Practices (GMP) certification, a standard required in China to produce pharmaceuticals or their ingredients.
Pursuant to the terms of the distribution agreement BodyTel granted FourMed the right to exclusively market the products of BodyTel in the eight Arabian countries, with the United
The agreement allows Caldera Medical access to the transobturator method for the surgical treatment of stress incontinence. The agreement also allows Caldera Medical to protect the uniqueness of
Under the terms of the agreement, Alfacell has granted BL&H exclusive rights in the defined territory for the marketing, sales and distribution of Onconase (ranpirnase). Alfacell has received
The acetylcholinesterase (AChE) program is being conducted under the agreement the company entered into with the Yissum R&D Company, the technology transfer arm of the Hebrew University of